Αποτελέσματα Αναζήτησης
Use our locator tool to find DESTINY clinical trial locations and contact information; for eligible patients with metastatic breast cancer.
Find information on Phase 3 fam- trastuzumab deruxtecan (DS-8201) trials; for eligible patients with metastatic breast cancer.
5 Ιουν 2024 · Results from the phase III DESTINY-Breast06 trial demonstrated clinically meaningful progression-free survival benefit with T-DXd vs single-agent chemotherapy for patients with HR+/HER2-low or HER2-ultralow metastatic breast cancer after progression on endocrine-based therapy with or without targeted therapy.
10 Οκτ 2024 · Late-breaking findings from the phase IIIb/IV, open-label DESTINY-Breast12 trial support the use of the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) in patients with HER2-positive metastatic breast cancer and brain metastases who have experienced disease progression on at least two therapies.
13 Σεπ 2024 · DESTINY-Breast12 is an open-label, multicenter, phase 3b/4 clinical trial designed to evaluate the efficacy and safety of ENHERTU (5.4 mg/kg) in patients with previously treated advanced/metastatic HER2 positive breast cancer.
HER2-Positive Metastatic Breast Cancer. DESTINY-Breast03. The safety of ENHERTU was evaluated in 257 patients with unresectable or metastatic HER2-positive breast cancer who received at least one dose of ENHERTU 5.4 mg/kg intravenously once every three weeks in DESTINY-Breast03. The median duration of treatment was 14 months (range: 0.7 to 30).
In the single-arm, phase 2 DESTINY-Breast01 trial, trastuzumab deruxtecan showed robust activity in patients with HER2-positive metastatic breast cancer who were refractory or resistant to trastuzumab emtansine; a population with scarce effective treatments.
